/Incyte%20Corp_%20office%20sign-by%20Bo%20Shen%20via%20iStock.jpg)
Incyte Corporation (INCY) is a Wilmington, Delaware–based global biopharmaceutical company focused on developing and marketing innovative therapies in oncology, immunology, dermatology, and inflammation. Founded in 2002, Incyte has grown into a large-cap biotech with a market cap of $13.3 billion.
INCY is all geared up its fiscal Q2 earnings for 2025 before the market opens on Tuesday, Apr. 29. Prior to this event, analysts project this biopharmaceutical company to report a profit of $1.13 per share, up 155.7% from a loss of $2.03 per share in the year-ago quarter. The company has missed Wall Street's bottom-line estimates in three of the last four quarters, while surpassing on one quarter.
For the full year, analysts expect INCY to report EPS of $4.76, up significantly from $0.08 in fiscal 2024.
INCY has rallied 13.2% over the past 52 weeks, outpacing both the S&P 500 Index's ($SPX) 12.3% gain, and the Health Care Select Sector SPDR Fund’s (XLV) 6.5% decline over the same time frame.
On June 16, Incyte shares climbed over 4% after the company unveiled promising clinical trial results for an experimental therapy aimed at treating a blood disorder. Positive data from two separate studies highlighted the treatment’s potential efficacy and safety, reinforcing confidence in Incyte’s research pipeline.
The encouraging results also strengthened investor optimism around the company’s efforts to expand beyond its flagship drug, Jakafi, and underscored its long-term growth potential.
Wall Street analysts are moderately optimistic about INCY’s stock, with a "Moderate Buy" rating overall. Among 25 analysts covering the stock, ten recommend "Strong Buy," 14 advise “Hold,” and one suggests a “Strong Sell” rating. The mean price target of $76.09 indicates a 26.8% potential upside from INCY’s current price levels.
